COMPANY RESEARCH昭衍新药 (JOINN Laboratories) offers PK, immunogenicity, molecular assays and bioanalysis. Services should be matched to the intended study and assay requirements.
Profile review: 2026-11-05 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
| Period | Currency / basis | Revenue | Net profit | Operating cash flow | Report |
|---|---|---|---|---|---|
| FY2025 2025-12-31 | CNY PRC Accounting Standards / consolidated | 1,657,624,302.72 | 297,841,047.52 Net income attributable to shareholders of the listed company | 444,566,722.13 | Original ↗ |
| 2026Q3 (YTD) 2026-09-30 | CNY PRC Accounting Standards / consolidated | 1,187,905,975.28 | 929,686,958.53 Net income attributable to shareholders of the listed company | 853,281,922.83 | Original ↗ |
Disease tags match recorded text mentions and require program-level verification.
PK, immunogenicity, molecular assays and bioanalysis
Specialist contract research/testing services
Centered on nonclinical safety assessment, with early biology, clinical and translational testing, and laboratory animal resources.
Listed as SSE 603127 / HKEX 06127; original 2025 annual and 2026Q3 (YTD) reports reviewed.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| Nonclinical safety and biological assessment | Not applicable (services/platform) · Drug research and manufacturing services for clients | Services / platform | Not applicable: service capabilities are not clinical drug candidates; E4 does not rate service quality. |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
JOINN Laboratories reported consolidated revenue of RMB1.188 billion, up 20.60%, and attributable net income of RMB929.7 million for the nine months ended September 30, 2026. Biological-asset fair-value changes contributed approximately RMB866.3 million in net gains, materially affecting reported earnings. The quarterly filing is unaudited and covers the year-to-date period.
Bio-S Pharmaceutical reported that its joint platform with XtalPi, Hangzhou Baijingyao Biotechnology, was unveiled in Shanghai on November 5. The partners described plans to combine AI-driven discovery with experimental validation, drug development, and clinical translation. The November 6 announcement presents an operating strategy and platform milestone, rather than a quantified licensing transaction or validated clinical outcome.
A Bioanalysis paper describes development and prevalidation of a Luminex xMAP assay for simultaneous domain-specific anti-drug antibody detection. Using PEGylated Cas9 as a model, the authors report adjustable bead ratios and on-demand coupling to accommodate different minimum required dilutions. The original abstract supports assay feasibility, rather than universal validation across multidomain therapeutics or demonstrated clinical benefit.
Labcorp published a conference-poster summary on independent RNA and DNA integrity assessment in cell and gene therapy bioanalysis. It evaluates Agilent TapeStation microfluidic electrophoresis as an orthogonal quality-control tool alongside qPCR and RT-qPCR, which do not directly measure overall integrity. The public summary describes the evaluation's objective and rationale, without quantitative performance results or peer-reviewed publication metadata.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.